Pharvaris NV Form 4 insider transactions

Viviane Monges, a Director of Pharvaris N.V., sold 11,969 shares of common stock on September 23, 2026 for $33.05 per share.

Peng Lu, President of Pharvaris N.V., reported multiple transactions in common stock on September 22, 2026.

Johannes Gerardus Christiaan Petrus Schikan, a Director of Pharvaris N.V., sold 800 shares of common stock on September 22, 2026 for $36.19 per share.

David W. Nassif, CFO / CLO of Pharvaris N.V., sold 6,000 shares of common stock on September 21, 2026 for $36.47 per share.

Peng Lu, President of Pharvaris N.V., sold 100,000 shares of common stock on September 17, 2026 for $35.00 per share.

Johannes Gerardus Christiaan Petrus Schikan, a Director of Pharvaris N.V., sold 200,000 shares of common stock on September 17, 2026 for $35.00 per share.

Elisabeth Bjork, a Director of Pharvaris N.V., sold 52,500 shares of common stock on September 17, 2026 for $37.89 per share.

Robert Glassman, a Director of Pharvaris N.V., sold 14,493 shares of common stock on September 17, 2026 for $38.56 per share.

Anne Lesage, Chief Early Development of Pharvaris N.V., sold 20,000 shares of common stock on September 17, 2026 for $38.27 per share.

Berndt Modig, Chief Executive Officer and a Director of Pharvaris N.V., reported a transaction in 300,000 shares of common stock on September 17, 2026.

Stefan Andreas Abele, Chief Technical Ops Officer of Pharvaris N.V., sold 46,400 shares of common stock on September 15, 2026.

Robert Glassman, a Director of Pharvaris N.V., sold 8,667 shares of common stock on September 15, 2026 for $38.27 per share.

Wim Souverijns, Chief Commercial Officer of Pharvaris N.V., sold 26,090 shares of common stock on September 14, 2026.

Peng Lu, President of Pharvaris N.V., sold 15,000 shares of common stock on September 11, 2026 for $40.13 per share.

Berndt Modig, Chief Executive Officer and a Director of Pharvaris N.V., sold 2,291 shares of common stock on September 14, 2026 for $39.40 per share.

Anne Lesage, Chief Early Development of Pharvaris N.V., sold 30,000 shares of common stock on September 10, 2026 for $38.30 per share.

Robert Glassman, a Director of Pharvaris N.V., sold 8,000 shares of common stock on September 9, 2026 for $37.55 per share.

Peng Lu, President of Pharvaris N.V., sold 15,000 shares of common stock on September 8, 2026 for $40.68 per share.

Berndt Modig, Chief Executive Officer and a Director of Pharvaris N.V., sold 2,292 shares of common stock on August 14, 2026 for $34.77 per share.

Peng Lu, President of Pharvaris N.V., reported multiple transactions in common stock on August 11, 2026.

Berndt Modig, Chief Executive Officer and a Director of Pharvaris N.V., sold 2,292 shares of common stock on July 13, 2026 for $34.97 per share.

Peng Lu, Chief Medical Officer of Pharvaris N.V., reported multiple transactions in common stock on July 11, 2026.

Pharvaris N.V. Director Johannes Schikan sold a total of 37,590 shares of common stock across two transactions on June 29 and June 30, 2026, under a pre-arranged 10b5-1 trading plan.

Pharvaris N.V. reports that Chief Early Development Officer Anne Lesage executed a series of stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Pharvaris N.V. executive Anne Lesage reported transactions involving company common stock, including the exercise of stock options and subsequent sales.

Pharvaris N.V. Director Johannes Schikan sold 2,400 shares of common stock for approximately $35.10 per share as part of a pre-arranged 10b5-1 trading plan.

Pharvaris N.V. Chief Medical Officer Lu Peng executed a Rule 10b5-1 trading plan involving stock option exercises and sales.

Pharvaris CEO Berndt Modig sold 2,291 shares of common stock on June 15, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Chief Medical Officer Peng Lu disposed of 117 shares of Pharvaris N.V. to satisfy tax obligations related to RSU vesting.

Chief Medical Officer Peng Lu reported the withholding of 109 shares of Pharvaris N.V. common stock to satisfy tax obligations.